Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: J Clin Psychopharmacol. 2016 Aug;36(4):347–354. doi: 10.1097/JCP.0000000000000511

Table 3.

Methamphetamine (MA) pharmacokinetic parameters following intravenous MA (15 mg and 30 mg) during treatment with ibudilast 20 mg twice daily (BID), 50 mg BID, or placebo BID in MA dependent volunteers (N=11).

Methamphetamine
Pharmacokinetic
Parameter		 Methamphetamine
dose (mg)		 Group Mean (Standard Error)
Placebo Ibudilast
20 mg BID		 Ibudilast
50 mg BID
Cmax (ng/ml) 15 34.6 (4.1) 36.6 (2.8) 27.8 (1.4)
30 64.9 (3.3) 61.7 (2.7) 61.9 (3.3)
Tmax (hr) 15 0.69 (0.21) 0.93 (0.20) 1.33 (0.18)
30 0.64 (0.17) 0.92 (0.16) 0.95 (0.18)
AUCto last time point 15 435 (33) 472 (39) 377 (23)*
30 943 (69) 895 (65) 808 (64)
AUC∞ (ng hr/ml) 15 797 (286) 539 (43) 417 (26)
30 1018 (82) 994 (76) 879 (79)
T½ (hr) 15 13.3 (2.7) 11.4 (0.5) 11.2 (0.6)
30 10.6 (0.9) 11.5 (0.7) 10.1 (1.0)
*

p < 0.01 for ibudilast 50 mg BID versus placebo